Aquestive Therapeutics, Inc. (AQST) — SEC Filings
Aquestive Therapeutics, Inc. (AQST) — 50 SEC filings. Latest: ARS (Apr 24, 2026). Includes 39 8-K, 3 10-Q, 3 SC 13G.
View Aquestive Therapeutics, Inc. on SEC EDGAR
Overview
Aquestive Therapeutics, Inc. (AQST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: Aquestive Therapeutics, Inc. filed an 8-K on March 30, 2026, to disclose information under Regulation FD. The filing includes a press release and exhibits related to a meeting, with various graphic files attached. No specific financial figures or material events beyond the disclosure itself are deta
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 47 neutral. The dominant filing sentiment for Aquestive Therapeutics, Inc. is neutral.
Filing Type Overview
Aquestive Therapeutics, Inc. (AQST) has filed 1 ARS, 39 8-K, 3 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G/A, 3 SC 13G with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of AQST's 45 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 31 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.5M |
| Net Income | -$20.2M |
Key Executives
- Dr. David J. Gury
- Mr. David M. S. Kim
Industry Context
Aquestive Therapeutics operates in the highly competitive pharmaceutical sector, focusing on developing and commercializing differentiated products. The industry is characterized by significant R&D investment, stringent regulatory hurdles, and the need for effective commercialization strategies to achieve market penetration and profitability.
Top Tags
8-K (10) · financials (10) · sec-filing (9) · disclosure (8) · filing (7) · 8-k (6) · financial-reporting (5) · regulation-fd (4) · pharmaceuticals (4) · corporate-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001398733-26-000022 | Unique identifier for this specific filing |
| SEC File Number | 001-38599 | Identifies the company's filing history with the SEC |
| Commission File Number | 82-3827296 | Another identifier for the company's filings |
| Net Loss | $20.2M | Increased from $16.7M in Q2 2024, indicating worsening profitability. |
| Revenue | $12.5M | Up 5.9% from $11.8M in Q2 2024, showing modest growth. |
| Accumulated Deficit | $602.3M | Grew from $582.1M, highlighting persistent unprofitability. |
| R&D Expenses | $10.1M | Increased from $9.5M in Q2 2024, reflecting ongoing investment. |
| SG&A Expenses | $16.8M | Increased from $15.2M in Q2 2024, driven by commercialization. |
| Revenue Growth | 5.9% | Percentage increase in revenue from Q2 2024 to Q2 2025. |
| ATM Offering Proceeds | $1.2M | Capital raised through At-The-Market offering in Q1 2025. |
| Report Date | 20250602 | Date of the 8-K filing |
| Reporting Period End | 2025-03-31 | Quarterly financial data is as of this date. |
| Filing Date | 2025-05-12 | The date the 10-Q was officially submitted to the SEC. |
| IRS Employer Identification No. | 82-3827296 | Company's tax identification number |
| Fiscal Year | 2024 | Reporting period for the 10-K |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aquestive Therapeutics, Inc. (AQST)?
Aquestive Therapeutics, Inc. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 39 8-K, 3 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AQST filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Aquestive Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aquestive Therapeutics, Inc. (AQST) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aquestive Therapeutics, Inc.?
Key financial highlights from Aquestive Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AQST?
The investment thesis for AQST includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aquestive Therapeutics, Inc.?
Key executives identified across Aquestive Therapeutics, Inc.'s filings include Dr. David J. Gury, Mr. David M. S. Kim.
What are the main risk factors for Aquestive Therapeutics, Inc. stock?
Of AQST's 45 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 31 low-risk.
What are recent predictions and forward guidance from Aquestive Therapeutics, Inc.?
Forward guidance and predictions for Aquestive Therapeutics, Inc. are extracted from SEC filings as they are enriched.